Belantamab mafodotin (Blenrep), pomalidomide (Pomalyst), and dexamethasone (BPd) was well tolerated and led to deep responses in patients with high-risk multiple myeloma.
In June 2025, the FDA granted priority review to the sNDA of revumenib (Revuforj) in relapsed/refractory NPM1 -mutant acute ...
Insider Luke Miels will replace Emma Walmsley at the $83 bln drugmaker. He starts with the same baggage of slow revenue ...
From more than 30 target action dates in the last three months of the year, BioSpace has narrowed the list to six regulatory ...
GSK plc (NYSE:GSK) plc Bank of America Global Healthcare Conference 2025 September 24, 2025 4:00 AM EDTCompany ParticipantsJulie Brown - CFO & ...
Following the Trump administration's plans to explore whether a widely available generic medication called leucovorin could cure autism, GSK (NYSE:GSK), which once manufactured and marketed the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback